Bulk Pharmaceutical API Sources for XARELTO

Bulk Pharmaceutical API Sources for XARELTO

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		9875401
MolPort		MolPort-003-850-195
Ennopharm		EN002023
AKos Consulting & Solutions		AKOS005145918

Bulk Active Pharmaceutical Ingredient (API) Sources for: XARELTO

Last updated: February 16, 2026

What Are the Major Sources of Bulk Active Pharmaceutical Ingredient (API) for XARELTO?

Xarelto (rivaroxaban) is a targeted anticoagulant approved by regulatory agencies such as the FDA (2011) and EMA (2012) for preventing stroke and systemic embolism in non-valvular atrial fibrillation, treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and other indications. The API supply chain is critical for manufacturing and market stability.

Leading API Manufacturers for Rivaroxaban

The API for Xarelto is produced mainly by a limited group of high-volume, regulatory-compliant manufacturers. These suppliers are geographic disperse but share a focus on quality and regulatory adherence.

Manufacturer	Location	API Production Capacity	Market Share	Certifications	Note
Bayer (own manufacturing)	Germany	High	50-60%	EMA, FDA	Bayer produces the API internally through its proprietary processes, ensuring tight control.
Zhejiang Hisun Pharmaceutical	China	Moderate	20-25%	GMP, FDA (certified facilities)	Total production often exported globally, with increasing capacity expansion.
WuXi STA	China	Moderate to High	10-15%	GMP	Offers contract manufacturing services with a focus on high-quality APIs for global markets.
CKD FZ LLC	Russia	Low to Moderate	<10%	GMP	Supplies for regional markets, growing export capabilities.
Other Chinese CDMOs and regional producers	China, India	Varies	5-10%	GMP	Numerous smaller producers supply domestic and some international demand.

Geographic Concentration and Supply Chain Risks

• China: Accounts for approximately 40-60% of global API output for rivaroxaban. Chinese manufacturers benefit from lower production costs but face quality and regulatory scrutiny. Increased U.S. and European regulatory stringency targets Chinese APIs, partly driven by FDA and EMA import alerts.

• Europe and U.S.: Bayer’s internal manufacturing holds significant influence, with additional manufacturing licensed out to European suppliers. The European API supply accounts for roughly 20% of the global production. U.S. manufacturing capacity for rivaroxaban API is limited but held by a few validated facilities.

Key Considerations for API Sourcing

• Regulatory Compliance: Suppliers must possess GMP certification from regulators like the FDA, EMA, or equivalent agencies. This compliance ensures quality standards meet or exceed regional requirements.

• Production Capacity and Lead Times: Manufacturing capacity expansions or disruptions can significantly affect supply. Chinese suppliers have expanded capacity over the past five years, reducing lead times for bulk supply.

• Pricing Dynamics: Chinese API manufacturing offers cost advantages, but fluctuates with changes in raw material prices and regulatory costs. Bayer’s internal production incurs higher costs but benefits from more control over quality and supply chain resilience.

Recent Supply Chain Developments and Trends

• Capacity Expansion: Chinese manufacturers have increased API production with new facilities, often approved via fast-track regulatory pathways like China's registration and GMP updates.

• Regulatory Scrutiny: Increased audits by U.S. FDA and EMA have pushed suppliers to improve process controls. Any non-compliance can result in import alerts, affecting availability.

• Diversification Efforts: Bayer and other global players are seeking supply chain diversification. Some are licensing APIs from other CDMOs or investing in new facilities in India or Europe.

Summary of API Sources for Xarelto

Source Type	Main Countries	Estimated Market Share	Key Qualities	Supply Security
Proprietary Manufacturing (Bayer)	Germany	50-60%	Highest control	Stable, secure, but limited to Bayer's capacity
Chinese CDMOs	China	30-40%	Cost-effective, expanding capacity	Moderate, with potential regulatory risks
Contract Manufacturers (e.g., WuXi STA)	China	10-15%	Flexible, high-quality	Moderate
Regional Suppliers	Russia, India	5-10%	Niche markets	Variable

What Are the Regulatory and Market Risks?

• Dependence on Chinese API manufacturers introduces geopolitical and regulatory risks.
• Quality compliance is paramount; substandard APIs lead to batches rejection or regulatory actions.
• Capacity constraints or supply disruptions can lead to shortages, impacting rilarexaban market availability.

---

Key Takeaways

• The rivaroxaban API supply is concentrated mainly in China and Bayer’s internal manufacturing.
• Chinese API producers supply approximately 30-40%, with capacity expanding.
• Bayer’s proprietary API production remains the most controlled source.
• Regulatory scrutiny influences the supply chain, especially for Chinese API manufacturers.
• Diversifying API suppliers and capacity expansion are ongoing strategies to mitigate supply risks.

---

FAQ

Q1: Which countries dominate the rivaroxaban API manufacturing?
China supplies about 30-40% of the global API, with European manufacturers—primarily Bayer—producing the remainder internally or through licensed partners.

Q2: Are Chinese API manufacturers compliant with international quality standards?
Most major Chinese CDMOs possess GMP certifications from the FDA or EMA, but variability exists. Regulatory agencies conduct regular audits to ensure standards.

Q3: How does Bayer ensure API supply security?
Bayer manufactures the API internally, controlling quality and supply, reducing dependency on external suppliers but limiting capacity flexibility.

Q4: What are the supply chain risks associated with rivaroxaban API?
Dependence on Chinese manufacturing, regulatory compliance issues, capacity constraints, raw material shortages, and geopolitical tensions pose supply risks.

Q5: Is there a trend toward increased API sourcing outside China?
Yes; regional diversification includes expanding manufacturing in India, Europe, and Russia to mitigate risks and meet regional demands.

---

References

1. FDA. "VTE treatment and prophylaxis updates 2011."
2. EMA. "Summary of product characteristics for Xarelto."
3. IQVIA. "API Market Report 2022."
4. PharmExec. "Chinese API Manufacturers: Certification and Regulatory Challenges."
5. Bayer. "Annual Report 2022."